Shuttle Pharmaceuticals engages Bush & Associates as new auditor, replacing Forvis Mazars

Shuttle Pharmaceuticals Holdings, Inc.

Audit Committee and full Board approved dismissal of Forvis Mazars, LLP, effective after filing of the Form 10-Q for the quarter ended September 30, 2026.
Bush & Associates CPA LLC engaged November 2, 2026 under an engagement letter dated October 19, 2026; Audit Committee approved in October 2026.
New auditor will audit FY ending December 31, 2026 financials and review interim quarters ending March 31, June 30 and September 30, 2027.
Company reports no disagreements with Forvis Mazars and no reportable events under Item 304(a)(1)(iv)/(v); no consultations with Bush & Associates in FY2024-2025 or interim period.
Signed by Christopher Cooper, Co-Chief Executive Officer, and dated November 6, 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.